Valproic acid

ArtNr	HY-10585-25g
Hersteller	MedChem Express
CAS-Nr.	99-66-1
Menge	25 g
Quantity options	10 mM/1 mL 1 g 25 g 500 mg 5 g
Kategorie	Inhibitors & Compound Libraries Small Molecules
Typ	Inhibitors
Specific against	other
Purity	99.19
Citations	[1]Han BR, et al. Valproic acid inhibits the growth of HeLa cervical cancer cells via caspase-dependent apoptosis. Oncol Rep. 2013 Dec;30(6):2999-3005.\|[2]Zhang ZH, et al. Valproic acid inhibits tumor angiogenesis in mice transplanted with Kasumi 1 leukemia cells. Mol Med Rep. 2013 Nov 28.\|[3]Cohen OS, et al. Acute prenatal exposure to a moderate dose of valproic acid increases social behavior and alters gene expression in rats. Int J Dev Neurosci. 2013 Dec;31(8):740-50.\|[4]Avery LB, et al. Valproic Acid Is a Novel Activator of AMP-Activated Protein Kinase and Decreases Liver Mass, Hepatic Fat Accumulation, and Serum Glucose in Obese Mice. Mol Pharmacol. 2014 Jan;85(1):1-10.\|[5]Valproic acid, et al. Histone deacetylase is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer, and teratogen. J Biol Chem. 2001 Sep 28;276(39):36734-41.\|[6]Platta CS, et al. Valproic acid induces Notch1 signaling in small cell lung cancer cells. J Surg Res. 2008 Jul;148(1):31-7.\|[7]Routy JP, et al. Valproic acid in association with highly active antiretroviral therapy for reducing systemic HIV-1 reservoirs: results from a multicentre randomized clinical study. HIV Med. 2012 May;13(5):291-6. Acta Pharmacol Sin. 2024 Jun 18.\|Biochem Biophys Res Commun. 2022.\|Biochim Biophys Acta Gene Regul Mech. 2020 Sep;1863(9):194597.\|Biomaterials. 2018 Dec 6;193:30-46.\|bioRxiv. 2023 Apr 21.\|Biotechnol Bioeng. 2021 Sep 3.\|Brain Science Advances. 2022 Feb.\|Cell Death Differ. 2023 Jun 15.\|EMBO J. 2021 Apr 28;e106771.\|FEBS Open Bio.2024 May 1.\|Genes. 2024 Sep 13.\|Genomics. 2024 May, 116, 3, 110838.\|J Agric Food Chem. 2024 Oct 23.\|J Biol Chem. 2023 Jan 31;102971.\|J Ethnopharmacol. 2023 Feb 17;116258.\|J Ethnopharmacol. 2024 Aug 16:118697.\|J Integr Med. 2024 Nov 8:S2095-4964(24)00397-2.\|J Virol. 2024 Nov 12:e0121624.\|Lett Drug Des Discover. 2019 Nov.\|Life Sci. 2023 Jul 8;121921.\|Mil Med Res. 2020 Nov 1;7(1):52.\|Mil Med Res. 2020 Sep 6;7(1):42. \|Nat Commun. 2024 Sep 19;15(1):8221.\|Oncogene. 2021 Apr;40(15):2711-2724.\|Phytomedicine. 19 August 2022, 154403.\|Research Square Preprint. 2022 Jan.\|Research Square Preprint. 2022 Jul.\|Sci Adv. 2021 Aug 11;7(33):eabf4416.\|Sci Rep. 2020 Sep 16;10(1):15201.\|Sci Total Environ. 2021, 147014.\|Sci Total Environ. 2023 Aug 23;903:166505.\|Signal Transduct Target Ther. 2024 Jan 22;9(1):24.\|STAR Protoc. 16 September 2022, 101638.\|Acta Pharmacol Sin. 2020 Jun 17. \|Adv Sci (Weinh). 2023 Dec 12:e2305620.\|BMC Cancer. 2022 Aug 8;22(1):864.\|Clin Dev Immunol. 2020 Aug 4;2020:4384696.\|Ecotoxicol Environ Saf. 2022 Jun 14;241:113752.\|J Genet Genomics. 2023 Sep 11;S1673-8527(23)00184-4.\|J Interferon Cytokine Res. 2021 Dec;41(12):439-449.\|Signal Transduct Target Ther. 2024 Oct 30;9(1):294.\|Toxicol Lett. 2021 Apr 24;346:47-56.\|Viruses. 2024 Apr 20;16(4):643.
Smiles	CCCC(CCC)C(O)=O
ECLASS 10.1	32160490
ECLASS 11.0	32160490
UNSPSC	12000000
Alias	Dipropylacetic Acid
Versandbedingung	Raumtemperatur
Lieferbar
Manufacturer - Type	Reference compound
Manufacturer - Applications	Cancer-Kinase/protease
Manufacturer - Targets	Apoptosis; Autophagy; Endogenous Metabolite; HDAC; HIV; Mitophagy; Notch; Organoid
Shipping Temperature	Room Temperature
Storage Conditions	Store at room temperature 3 years
Molecular Weight	144.21
Product Description	Valproic acid (VPA) is an orally active HDAC inhibitor, with IC50 in the range of 0.5 and 2 mM. Valproic acid inhibits HDAC1 (IC50, 400 μM), and induces proteasomal degradation of HDAC2. Valproic acid activates Notch1 signaling and inhibits proliferation in small cell lung cancer (SCLC) cells. Valproic acid is used in the epilepsy, bipolar disorder, metabolic disease, HIV infection and prevention of migraine headaches[1][2][3][4][5][6][7].
Manufacturer - Research Area	Cancer; Infection; Metabolic Disease; Neurological Disease
Solubility	0.1 M NaOH: 50 mg/mL (ultrasonic)\|DMSO: 100 mg/mL (ultrasonic)\|H2O: 2.5 mg/mL (ultrasonic; warming; heat to 60°C)
Manufacturer - Pathway	Anti-infection; Apoptosis; Autophagy; Cell Cycle/DNA Damage; Epigenetics; Metabolic Enzyme/Protease; Neuronal Signaling; Stem Cell/Wnt
Isoform	HDAC; HDAC1; HDAC2
Clinical information	Launched

Hinweis: Die dargestellten Informationen und Dokumente (Bedienungsanleitung, Produktdatenblatt, Sicherheitsdatenblatt und Analysezertifikat) entsprechen unserem letzten Update und sollten lediglich der Orientierung dienen. Wir übernehmen keine Garantie für die Aktualität. Für spezifische Anforderungen bitten wir Sie, uns eine Anfrage zu stellen.

Alle Produkte sind nur für Forschungszwecke bestimmt. Nicht für den menschlichen, tierärztlichen oder therapeutischen Gebrauch.

Arbeitsanleitung (Data Sheet) anfordern

Produkt-Datenblatt anfordern

HY-10585-25g-safety-datasheet.pdf